PSMA-PET/CT using PROMISE V2 standards detects lesions <5 mm with 98% sensitivity [254, 255]Gene therapy with BMP7 induces tumor cell dormancy with 68% maintenance rate (279, 280). This evidence concerns the gene FOLH1 and neoplasm.